Cargando…

Patient and Caregiver Experiences With and Perceptions of Risk Evaluation and Mitigation Strategy Programs With Elements to Assure Safe Use

IMPORTANCE: The US Food and Drug Administration (FDA) Amendments Act of 2007 authorized the FDA to impose safety requirements on drugs with important risks, such as prescriber certification or routine laboratory testing, to ensure that the benefits of use outweighed the risks. However, little is kno...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sarpatwari, Ameet, Brown, Beatrice L., McGraw, Sarah A., Dejene, Sara Z., Abdurrob, Abdurrahman, Santiago Ortiz, Adrian J., Kesselheim, Aaron S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2022
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777595/ https://www.ncbi.nlm.nih.gov/pubmed/35050352 http://dx.doi.org/10.1001/jamanetworkopen.2021.44386

Ejemplares similares

Physician experiences with and perceptions of risk evaluation and mitigation strategy programs with elements to assure safe use
por: Sarpatwari, Ameet, et al.
Publicado: (2023)

Analysis of risk evaluation and mitigation strategies for teratogenic drugs: Variation in primary and secondary prevention measures
por: Brown, Beatrice L., et al.
Publicado: (2023)

Outcomes of the 340B Drug Pricing Program: A Scoping Review
por: Knox, Ryan P., et al.
Publicado: (2023)

The Case for Reforming Drug Naming: Should Brand Name Trademark Protections Expire upon Generic Entry?
por: Sarpatwari, Ameet, et al.
Publicado: (2016)

Regulatory Solutions to the Problem of High Generic Drug Costs
por: Luo, Jing, et al.
Publicado: (2015)

Paying Physicians to Prescribe Generic Drugs and Follow-On Biologics in the United States
por: Sarpatwari, Ameet, et al.
Publicado: (2015)

Competition and price among brand-name drugs in the same class: A systematic review of the evidence
por: Sarpatwari, Ameet, et al.
Publicado: (2019)

The effect of federal and state off-label marketing investigations on drug prescribing: The case of olanzapine
por: Wang, Bo, et al.
Publicado: (2017)

Competition law and pricing among biologic drugs: the case of VEGF therapy for retinal diseases
por: Van de Wiele, Victor L, et al.
Publicado: (2022)

US public investment in development of mRNA covid-19 vaccines: retrospective cohort study
por: Lalani, Hussain S, et al.
Publicado: (2023)

Correlation of Health Insurance Provider to Orthopedic Patient Reported Outcome Measures
por: Smith, Jeremy T., et al.
Publicado: (2019)

Risk Evaluation and Mitigation Strategies (REMSs): Are They Improving Drug Safety? A Critical Review of REMSs Requiring Elements to Assure Safe Use (ETASU)
por: Boudes, Pol F.
Publicado: (2017)

Differences in rates of switchbacks after switching from branded to authorized generic and branded to generic drug products: cohort study
por: Desai, Rishi J, et al.
Publicado: (2018)

Mifepristone, preemption, and public health federalism
por: Zettler, Patricia J, et al.
Publicado: (2022)

Comparative effectiveness of generic and brand-name medication use: A database study of US health insurance claims
por: Desai, Rishi J., et al.
Publicado: (2019)

COVID-19 antivirals must not affect HIV drug supply
por: Barber, Melissa, et al.
Publicado: (2022)

What are the Essential Elements to Enable Patient Participation in Medical Decision Making?
por: Fraenkel, Liana, et al.
Publicado: (2007)

Mitigating bias in machine learning for medicine
por: Vokinger, Kerstin N., et al.
Publicado: (2021)

Use of Extrapolation in New Drug Approvals by the US Food and Drug Administration
por: Feldman, Daniel, et al.
Publicado: (2022)

Assuring Access to Safe Medicines in Pregnancy and Breastfeeding
por: Nooney, Janet, et al.
Publicado: (2021)

A Comparison of Response Patterns for Progression-Free Survival and Overall Survival Following Treatment for Cancer With PD-1 Inhibitors: A Meta-analysis of Correlation and Differences in Effect Sizes
por: Gyawali, Bishal, et al.
Publicado: (2018)

Variation in Use of Lung Cancer Targeted Therapies Across State Medicaid Programs, 2020-2021
por: Roberts, Thomas J., et al.
Publicado: (2023)

The Nature and Extent of Mutational Pleiotropy in Gene Expression of Male Drosophila serrata
por: McGuigan, Katrina, et al.
Publicado: (2014)

Caregiver Perceptions of Children’s Psychological Well-being During the COVID-19 Pandemic
por: Raviv, Tali, et al.
Publicado: (2021)

Variation in Crossover Frequencies Perturb Crossover Assurance Without Affecting Meiotic Chromosome Segregation in Saccharomyces cerevisiae
por: Krishnaprasad, Gurukripa N., et al.
Publicado: (2015)

Variations in Use of Diabetes Drugs With Cardiovascular Benefits Among Medicaid Patients
por: Zhai, Mike Z., et al.
Publicado: (2022)

Assessing the Justification, Funding, Success, and Survival Outcomes of Randomized Noninferiority Trials of Cancer Drugs: A Systematic Review and Pooled Analysis
por: Gyawali, Bishal, et al.
Publicado: (2019)

Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
por: Cherla, Avi, et al.
Publicado: (2021)

Public Approval of Exception From Informed Consent in Emergency Clinical Trials: A Systematic Review of Community Consultation Surveys
por: Feldman, William B., et al.
Publicado: (2019)

Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis
por: D’Andrea, Elvira, et al.
Publicado: (2019)

Correlation Between Changes in Brand-Name Drug Prices and Patient Out-of-Pocket Costs
por: Rome, Benjamin N., et al.
Publicado: (2021)

Association of Advisory Committee Votes With US Food and Drug Administration Decision-Making on Prescription Drugs, 2010-2021
por: Daval, C. Joseph Ross, et al.
Publicado: (2023)

National Comprehensive Cancer Network Guideline Recommendations of Cancer Drugs With Accelerated Approval
por: Cliff, Edward R. Scheffer, et al.
Publicado: (2023)

Analysis of Supportive Evidence for US Food and Drug Administration Approvals of Novel Drugs in 2020
por: Mitra-Majumdar, Mayookha, et al.
Publicado: (2022)

Therapeutic Value of Drugs Granted Accelerated Approval or Conditional Marketing Authorization in the US and Europe From 2007 to 2021
por: Vokinger, Kerstin N., et al.
Publicado: (2022)

Estimates of Medicaid and Non-Medicaid Net Prices of Top-Selling Brand-name Drugs Incorporating Best Price Rebates, 2015 to 2019
por: Clemans-Cope, Lisa, et al.
Publicado: (2023)

Outcomes of Isolated Peroneal Tendoscopy for Treatment of Peroneal Tendon Disorders
por: Smith, Jeremy T., et al.
Publicado: (2019)

Characterization and mitigation of aerosols and spatters from ultrasonic scalers
por: Ou, Qisheng, et al.
Publicado: (2021)

Caregiver acceptance of an anticipated COVID-19 vaccination
por: Marquez, Ronnie R., et al.
Publicado: (2021)

Differences in Diabetic Prescription Drug Utilization and Costs Among Patients With Diabetes Enrolled in Colorado Marketplace and Medicaid Plans, 2014-2015
por: Khorrami, Peggah, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_24vst2b7mac3tp3pbd32j03re0